Advanced search

News (201)

Transcript : Vertex Pharmaceuticals Incorporated - Special Call	Apr. 10
Transcript : Vertex Pharmaceuticals Incorporated - Special Call	Apr. 10
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	Apr. 10	BU
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	Apr. 10	BU
Vertex Pharmaceuticals Incorporated : ID&E Fact Sheet	Mar. 04	PU
Vertex Pharmaceuticals - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	Feb. 14	AQ
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	Feb. 13	BU
Vertex Pharmaceuticals 4Q Net, Revenue Beat Estimates	Feb. 05	DJ
Transcript : Vertex Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 05, 2024	Feb. 05
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 05	BU
Transcript : Vertex Pharmaceuticals Incorporated - Special Call	Jan. 30
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain	Jan. 30	BU
Vertex Announces US FDA Approval of CASGEVY for the Treatment of Transfusion-Dependent Beta Thalassemia	Jan. 17	AQ
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia	Jan. 16	BU
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Arabia	Jan. 10	AQ
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia	Jan. 09	BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM	Jan. 08
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings	Jan. 07	BU
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8	Dec. 18	BU
Transcript : Vertex Pharmaceuticals Incorporated - Special Call	Dec. 13
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY for the Treatment of Sickle Cell Disease	Dec. 11	AQ
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease	Dec. 08	BU
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	Nov. 17	AQ
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	Nov. 16	BU
Vertex Pharmaceuticals Incorporated : Q3 2023 Presentation	Nov. 06	PU
Transcript : Vertex Pharmaceuticals Incorporated, Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06
Vertex Reports Third Quarter 2023 Financial Results	Nov. 06	BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 11:30 AM	23-09-13
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13	23-08-30	BU
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations	23-08-29	BU
Vertex Pharmaceuticals Incorporated : Q2 2023 Presentation	23-08-01	PU
Transcript : Vertex Pharmaceuticals Incorporated, Q2 2023 Earnings Call, Aug 01, 2023	23-08-01
Vertex Reports Second Quarter 2023 Financial Results	23-08-01	BU
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies	23-06-27	AQ
Lonza and Vertex to partner to manufacture diabetes cell therapies	23-06-27	AQ
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies	23-06-26	BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 02:40 PM	23-06-13
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	23-06-08	BU
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13	23-05-30	BU
Vertex Pharmaceuticals Incorporated : Confirms growth trajectory	23-05-04
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2023 Earnings Call, May 01, 2023	23-05-01
Vertex Reports First Quarter 2023 Financial Results	23-05-01	BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at Cowen 43rd Annual Healthcare Conference, Mar-07-2023 02:50 PM	23-03-07
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Cowen 43rd Annual Healthcare Conference, Mar-06-2023 through Mar-08-2023	23-03-06
Transcript : Vertex Pharmaceuticals Incorporated, Q4 2022 Earnings Call, Feb 07, 2023	23-02-07

1234NextSee all

Insiders

Reshma Kewalramani

Reshma Kewalramani is President, Chief Executive Officer & Director at Vertex Pharmaceuticals, Inc. In the past she was VP-Global Clinical Development & Nephrology at Amgen, Inc. She received a doctorate from Boston University School of Medicine.

Devika Kewalramani

Devika Kewalramani currently works at The Association of the Bar of the City of New York, as Director & Vice President from 2023.

Ritesh Kewalramani

Bharat Kewalramani

Bharat Kewalramani is currently the Managing Director & Director at 3D Technopack Ltd.
He previously worked as a Director at Piramal Glass Pvt Ltd.
from 2007 to 2011.

Sachin Kewalramani

Dalip Kumar Kewalramani

Rishabh Kewalramani

Tarun Kewalramani

Piyush suresh Kewalramani

Dalip Kewalramani

No results for this search

Stock Market
Advanced search
Reshma Kewalramani